New Drugs and Drug News: The 411 and Implications for Palliative Care (TH365)

Up to 100 new drugs and dosage formulations are approved every year by the Food and Drug Administration (FDA). Some of these are new molecular entities, while others are new formulations, new indications, generic drug approvals, or labeling revisions. Even if a drug is a “new” molecular entity, it may not be “improved” over molecular entities already commercially available. In caring for patients with advanced illnesses, practitioners must make prudent drug therapy choices. Part of this decision-making process is a careful assessment of the burden-to-benefit ratio, including the financial burden of using each medication.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research